AESEG and EGA cooperate to bring generic drugs to Spanish market

At their joint executive meeting in Barcelona yesterday, the Spanish Generic Medicines Association (AESEG) and the European Generic and Biosimilar Medicines Association (EGA) confirmed their commitment to join forces and bring access to generic medicines to the Spanish market, reinforcing the industry’s commitment to increase patient access to high quality medicines.

A recent IGES study has shown that better access to generic medicines can have significant health outcome benefits for patients.

The AESEG and EGA executives debated the importance of re-introducing price differentiation between originator and generic medicines to stimulate competition, the negative consequences of the procurement system in Andalusia and the SPC (Supplementary Protection Certificate) manufacturing waiver proposal which would create thousands of jobs for the Spanish pharmaceutical industry.